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Kaposi’s sarcoma (KS) is a multicentric angioproliferative malig­
nancy of endothelial cell origin associated with human herpesvirus 8 
infection. KS typically occurs in the setting of immunodeficiency 
and specifically in the presence of HIV infection, when it is 
called AIDS­associated KS (AIDS­KS). AIDS­KS is classified as 
an AIDS­defining cancer. It is characterised by a wide variation in 
clinical presentations and course of disease. Since the widespread 
introduction of antiretroviral therapy (ART) in Europe and North 
America in the 1990s, the incidence of and mortality from AIDS­KS 
have decreased dramatically.[1] Similar trends have been reported in 
sub­Saharan countries, but in spite of impressive gains in the South 
African (SA) ART roll­out programme since 2004, AIDS­KS remains 
a condition that causes significant morbidity and mortality in the SA 
HIV­infected population.[2­7] A recent publication estimated the SA 
AIDS­KS incidence rate in patients recently initiated on ART as 138 
per 100 000 person­years.[8] The modified AIDS Clinical Trials Group 
(ACTG) staging system classifies AIDS­KS as either limited disease 
with a good prognosis or advanced disease with a poorer prognosis.[9] 
The treatment of advanced AIDS­KS can be challenging in SA owing 
to the centralisation of oncology services to tertiary hospitals and 
the high incidence of concurrent opportunistic infections (OIs).[10] 
The Tygerberg Hospital (TBH) infectious diseases clinic is a tertiary 
referral centre in a high HIV prevalence setting in Cape Town, 
SA. In 2014, a weekly multidisciplinary AIDS­KS clinic (MKSC) 
was established in collaboration with the TBH oncology division 
to evaluate all new cases of AIDS­KS with the goal of optimising 
management of patients in the drainage area by improving access to 
these specialist clinical services. A management and referral standard 
operating procedure was developed and the MKSC was promoted to 
referring clinics via provincial structures.
Objectives
To describe patients with AIDS­KS referred to the MKSC in terms 
of demographic and disease characteristics, treatment and outcomes, 
and to analyse the associations between these factors. The primary 
objective was to report on overall survival (OS) from diagnosis with 
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Objectives. To report on the characteristics and outcomes of patients seen during the first 6 months after the inception of the MKSC.
Methods. A retrospective observational study was performed of all new cases referred to the MKSC from February to August 2014.
Results. Forty­two patients were included in the study. The median age was 34 years (range 20 ­ 60). Forty­one patients were on ART at time 
of diagnosis or were initiated by a median of 3 months after diagnosis. The median CD4+ count before diagnosis was 147 cells/µL (range 4 ­ 
811). The HIV viral load was undetectable in 22 cases (52.4%). Thirty­eight patients (90.5%) were classified as AIDS Clinical Trials Group 
(ACTG) poor risk, 10 patients (23.8%) had visceral KS, 14 patients (33.3%) were on tuberculosis (TB) treatment at time of presentation, 
and 22 patients (52.4%) received oncological therapy in addition to ART. After median follow­up of 25.6 months, 2­year overall survival 
(OS) was 61.1%. On univariate analysis, factors significantly associated with poor 2­year OS included ACTG S1 stage (S = systemic illness), 
visceral KS, being on TB treatment, and Eastern Cooperative Oncology Group performance status score >2. In the T1 (T = tumour extent) 
subgroup, receiving chemotherapy was significantly associated with improved 2­year OS.
Conclusions. Advanced AIDS­KS significantly affects young people in the Western Cape Province of SA despite 10 years of ART roll­out. 
There is a high prevalence of concomitant TB infection that could adversely affect adherence and response to treatment. Despite advanced 
disease at presentation and palliative treatment intent, survival outcomes are encouraging and seem to be positively affected by the increased 
use of chemotherapy. A multidisciplinary approach to diagnosis, staging and treatment and the exploration of prognostic indices specific to 
the sub­Saharan setting would be valuable in designing appropriate treatment algorithms.
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KS for the entire cohort. The secondary objectives were to report 
on the 2­year OS from diagnosis with KS for selected subgroups 
and on statistical associations between selected clinically relevant 
demographic, disease or treatment characteristics and the primary 
outcome.
Methods
The clinical records of all patients with AIDS­KS assessed at the MKSC 
between February and August 2014 were retrospectively reviewed. 
Patients were excluded if they had a second malignancy that required 
more urgent therapy than their KS. Data collected included patient 
demographics (age at diagnosis, gender and clinician­reported ethnic 
group), ART initiation and duration, CD4+ count at diagnosis, HIV 
viral load (VL) at referral, presence of OIs, histological findings, 
KS stage according to the modified ACTG staging system (Table 1) 
and sites of involvement, presence of oedema, performance status 
(PS), and treatment modalities and responses.[9] Survival outcomes 
were defined as death, loss to follow­up (LTFU) or alive, and were 
censored on 4 September 2016. LTFU status was assigned if the living 
status of a patient could not be determined on the censoring date. 
These patients were censored on the date of last attendance. Time 
to death or LTFU was defined as number of months from diagnosis 
of KS. Living status was determined from hospital records and the 
national death registry. Descriptive statistics were used to report the 
prevalence of individual variables and the Kaplan­Meier method 
was used to estimate survival outcomes. The log­rank test was used 
to assess differences in survival distributions. Incidence rate ratios 
(IRRs) and 95% confidence intervals (CIs) were calculated. A p­value 
of <0.05 was considered statistically significant. Ethics approval was 
obtained from the Stellenbosch University Human Research Ethics 
committee (ref. no. M15/10/048).
Results
A total of 42 patients with a median age at AIDS­KS diagnosis of 
34 years (range 20 ­ 60) were included in the analysis. Twenty­three 
patients (54.8%) were female. Thirty­six patients (85.7%) were black, 
and the remainder were coloured.
Twenty­eight patients (66.7%) were on ART before KS diagnosis. 
The median number of weeks on ART was 12.5 (range 0 ­ 643). A 
further 13 patients (30.9%) were started on ART within a median of 
3 weeks after KS diagnosis, bringing the total number of patients on 
ART to 41 (97.6%). The specific ART regimens were not recorded. 
The median CD4+ count at the time of diagnosis was 147 cells/
µL (range 4 ­ 811), with 21 patients (50%) having a CD4+ count 
<150 cells/µL. VL at time of referral to the MKSC was known to 
be undetectable in 22 cases (52.4%) and was unknown in 12 cases 
(28.6%).
Forty patients (95.2%) had histologically confirmed KS. The 
remaining 2 patients were diagnosed clinically. Four patients (9.5%) 
were classified as ACTG good risk (T0I0S0, where T = tumour 
extent, I = immune status and S = systemic illness) and 38 (90.5%) 
as poor risk. Thirty­six patients (85.7%) were T1 and 20 (47.6%) 
were S1. The S1 cohort represents the T1S1 cohort, as there were 
no cases of T0S1 disease. Seven patients (16.7%) had an Eastern 
Cooperative Oncology Group (ECOG) PS score of >2. ECOG PS 
was undocumented in 17 cases (40.5%). The most common sites of 
involvement were the skin of the lower limbs (n=26 cases, 61.9%) 
and the oral mucosa (n=21, 50.0%). Twenty­one patients (50.0%) had 
documented oedema. Ten patients (23.8%) had visceral KS, 3 with 
pulmonary KS (radiological diagnosis), 6 with gastrointestinal tract 
(GIT) KS (endoscopic diagnosis) and 1 with both.
Fourteen patients (33.3%) were on TB treatment at time of 
referral to the MKSC. Other co­infections recorded included syphilis, 
toxoplasmosis, cryptococcal meningitis, oral candida, Klebsiella 
pneumonia and superficial infection of KS skin lesions.
All treatment decisions were made by the multidisciplinary 
team (MDT) consisting of infectious diseases physicians, clinical 
oncologists and dermatologists. Twenty patients (47.6%) received 
ART only and 22 (52.4%) received ART and oncological therapy 
(Table 2).
Three distinct treatment groups were identified retrospectively 
based on the type of therapy received as recommended by the 
MDT (Table 3). Ten patients had T0 (n=6) or T1 (n=4) disease 
that was responding clinically to ART and received no oncological 
treatment in addition to continued ART (group 1). This group 
included 2 patients with T1S1 disease. The remaining 32 patients had 
symptomatic T1 (n=18 T1S1) disease that was not responding to ART 
adequately and were considered for oncotherapy. Of these patients, 22 
(n=9 T1S1) received additional oncological treatment (group 2). Six 
were on TB treatment and 6 had visceral KS. Thirteen patients had 
chemotherapy alone, 3 had radiotherapy (RT) alone and 6 had both. 
The median dose of RT was 8 Gy (range 6 ­ 30.25). Three patients had 
multiple sites of RT. One patient underwent intraocular bleomycin 
administration and the remainder received systemic combination 
chemotherapy. Two patients received second­line chemotherapy for 
progressive AIDS­KS. The remaining 10 patients (n=9 T1S1) did not 
receive oncological treatment in addition to ART because they either 
defaulted from care (n=2) or were found to be unfit for oncological 
therapy (n=8) (group 3). Six of these patients were on TB treatment 
and 4 had visceral KS.
Table 1. ACTG modified staging classification for AIDS-KS[9]
Good risk (all of the following) Poor risk (any of the following)
T T0: confined to skin and/or lymph nodes and/or minimal 
oral disease (non­nodular KS confined to palate)
T1: tumour­associated oedema or ulceration
Extensive oral KS
Gastrointestinal KS
KS in other non­nodal viscera
I I0: CD4+ cell count >150/µL I1: CD4+ cell count <150/µL
S S0: no history of OI or thrush
No ‘B’ symptoms
Karnofsky PS >70
S1: history of OI and/or thrush
‘B’ symptoms present
Karnofsky PS <70
Other HIV­related illness (e.g. neurological disease, 
lymphoma)
ACTG = AIDS Clinical Trials Group; AIDS­KS = AIDS­associated Kaposi’s sarcoma; T = tumour extent; I = immune status; S = systemic illness; OI = opportunistic infection;  
KS = Kaposi’s sarcoma; ‘B’ symptoms = unexplained fever, night sweats, <10% involuntary weight loss, or diarrhoea persisting >2 weeks; PS = performance status. 
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Response to RT or chemotherapy was assessed at 6 weeks from 
completion of treatment. Patients with lasting complete or partial 
response (PR) from baseline were referred to their ART clinic for 
follow­up with instructions to refer the patient back if progressive 
disease was noted. The attendance rate at 6 weeks after RT was 
44.4%. All these patients had PR as defined by any improvement 
in symptoms or reduction in size of target lesions lasting for 
6  weeks after completion of treatment. All but one of the patients 
treated with systemic therapy received adriamycin (40 mg/mm²), 
bleomycin (10  IU/mm²) and vinblastine (6 mg/mm²) combination 
chemotherapy prescribed on a 4­weekly basis for 6 cycles. One 
patient received bleomycin (15 IU/mm²) and vincristine (2 mg) given 
on a 3­weekly basis owing to a change in departmental protocol from 
2015. Nine of 19 patients (47.4%) completed the intended number 
of cycles (median 4, range 1 ­ 8). A significant delay of 14 days or 
more was seen in only 4 patients (19.1%) (median 3 days, range 0 ­ 
37). Seven of the 19 (36.8%) attended the follow­up visit 6 weeks 
after completing chemotherapy. Six (31.6%) demonstrated PR and 1 
(5.3%) had stable disease. Overall, 7 patients (31.8%) defaulted from 
oncological treatment, but 17 (77.3%) defaulted from follow­up at 
some point. There were 2 deaths on chemotherapy. The exact cause 
of death was not known in either case.
After a median follow­up from diagnosis of 25.6 months (range 
0.3 ­ 32.6), there had been 16 deaths (38.1%). Cumulative 2­year 
OS from diagnosis was 61.1% and the median OS was not reached 
(Table 4). Cumulative 2­year OS for S0 and S1 disease was 81.3% 
and 38.5%, respectively (p=0.001, IRR 5.88, 95% CI 1.78 ­ 25.0) 
(Fig. 1). Patients without visceral disease had a cumulative 2­year 
Table 2. Demographic, disease and treatment characteristics 
(N=42)
Age (years), median (range) 34 (20 ­ 60)
Gender, n (%)
Female 23 (54.8)
Male 19 (45.2)
Ethnic group, n (%)
Black 36 (85.7)
Coloured 6 (14.3)
ART initiation, n (%)
Before KS diagnosis 28 (66.7)
After KS diagnosis 13 (30.9)
Not initiated 1 (2.4)
CD4+ count (cells/µL)
Median (range) 147 (4 ­ 811)
<150, n (%) 21 (50.0)
VL undetectable, n (%)
Yes 22 (52.4)
No 8 (19.0)
Unknown 12 (28.6)
KS stage, n (%)
Good risk 4 (9.5)
Poor risk 38 (90.5)
T0 6 (14.3)
T1 36 (85.7)
S0 22 (52.4)
S1 (T1S1)* 20 (47.6)
ECOG PS, n (%)
≤2 18 (42.9)
>2 7 (16.7)
Unknown 17 (40.5)
Site of KS involvement, n (%)
Lower limb 26 (61.9)
Oral cavity 21 (50.0)
Oedema 21 (50.0)
Visceral KS, n (%)
Any 10 (23.8)
GIT† 7 (16.7)
Pulmonary‡ 4 (11.9)
OI, n (%)
TB§ 14 (33.3)
Other OI 4 (9.5)
Treatment, n (%)
ART 41 (97.6)
Chemotherapy 19 (45.2)
Radiotherapy 9 (21.4)
ART = antiretroviral therapy; KS = Kaposi’s sarcoma; VL = viral load; T = tumour extent, 
S = systemic symptoms (AIDS Clinical Trials Group staging); ECOG PS = Eastern 
Cooperative Oncology Group performance status; GIT = gastrointestinal;  
TB = tuberculosis; OI = opportunistic infection.
*No cases of T0S1 disease noted.
†Endoscopically proven cases.
‡Radiological diagnosis.
§On TB treatment.
Table 3. Retrospective treatment groups according to T stage
Treatment group Treatment ACTG T stage, n
1 ART alone T0 6, T1 4
2 ART and RT and/or 
chemotherapy
T0 0, T1 22
3 ART alone T0 0, T1 10
T = tumour extent; ACTG = AIDS Clinical Trials Group; ART = antiretroviral therapy;  
RT = radiotherapy.
Table 4. OS according to demographic and clinical factors
2-year 
OS from 
diagnosis, % p-value (IRR, 95% CI)
All (N=42) 61.1
ACTG S1 (T1S1) 0.001 (5.88, 1.78 ­ 25.0)
Yes (n=20) 38.5
No (n=22) 81.3
Known visceral KS 0.03 (3.53, 1.05 ­ 10.71)
Yes (n=10) 36.0
No (n=32) 68.4
Known pulmonary KS 0.004 (11.54, 2.11 ­ 42.01)
Yes (n=4) 0
No (n=38) 64.9
Known ECOG PS >2 0.01 (6.2, 1.34 ­ 31.4)
Yes (n=7) 28.6
No (n=35) 67.7
Any OI 0.0005 (6.29, 2.01 ­ 23.08)
Yes (n=17) 33.1
No (n=25) 79.6
On TB treatment 0.0031 (4.67, 1.55 ­ 14.74)
Yes (n=14) 32.7
No (n=28) 74.7
OS = overall survival; IRR = incidence rate ratio; CI = confidence interval; ACTG = AIDS 
Clinical Trials Group; T = tumour extent; S = systemic symptoms; KS = Kaposi’s sarcoma; 
ECOG PS = Eastern Cooperative Oncology Group performance status; OI = opportunistic 
infection; TB = tuberculosis.
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OS of 68.4% compared with 36.0% in patients with visceral disease 
(p=0.03, IRR 3.53, 95% CI 1.05 ­ 10.71) (Fig. 2). Other demographic 
and disease factors that negatively affected survival outcome were 
pulmonary involvement, being on TB treatment, ECOG PS >2 and 
the presence of any OI (Table 4). T1 disease, I1 disease, ACTG poor­ 
risk group, gender, ethnic group, ART before KS diagnosis, VL lower 
than detectable limit, oedema, specific skin sites, oral involvement and 
GIT involvement were not significantly associated with 2­year OS.
The 2­year OS according to treatment group was 90%, 70.9% and 
10% for groups 1, 2 and 3, respectively (p<0.001) (Table 5). In the T1 
subgroup, 2­year OS by treatment group was 100%, 70.9% and 10%, 
respectively (p<0.001) (Fig. 3). T1 patients receiving chemotherapy 
had a 2­year OS of 77.3% v. 35.3% for those without chemotherapy 
(p=0.0019, IRR 0.18, 95% CI 0.04 ­ 0.61). In the T1 subgroup not 
responding optimally to ART, the 2­year OS was 15.4% (p<0.001, 
IRR 0.09, 95% CI 0.02 ­ 0.3) (Fig. 4).
Discussion
One of the challenges in treating advanced AIDS­KS is the lack of 
multidisciplinary input in the accurate diagnosis, staging and treatment 
selection of patients.[5] During the first 6 months after its establishment, 
the MKSC assessed 42 new AIDS­KS patients.
The median age at KS diagnosis of 34 years is similar to that reported 
in three other SA cohorts.[5,11,12] Although this finding can be expected 
 
Figure 1: 2yr OS by S stage (p<0.001) 
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Fig. 1. Two-year overall survival according to S stage (p<0.001). (S = 
systemic illness.)
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Fig. 2. Two-year overall survival according to visceral KS (p=0.03). (KS = 
Kaposi’s sarcoma.)
 
 
Figure 3: T1 2yr OS by treatment group (p<0.001) 
 
 
Figure 4: 2yr OS by chemotherapy in T1 with suboptimal response to ART (p<0.001) 
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Fig. 3. Two-year overall survival in T1 according to treatment group (see 
text for description of the treatment groups) (p<0.001). (T = tumour extent.)
Table 5. OS according to treatment
Treatment type
All (N=42) T1 (N=36)
T1 with suboptimal response to ART 
(N=32)
2-year 
OS from 
diagnosis (%)
p-value  
(IRR, 95% CI)
2-year 
OS from 
diagnosis (%)
p-value  
(IRR, 95% CI)
2-year  
OS from 
diagnosis (%)
p-value  
(IRR, 95% CI)
Treatment group* <0.001 <0.001 <0.001
1 90.0 100 NA
2 70.9 70.9 70.9
3 10.0 10 10.0
Chemotherapy 0.023  
(0.29, 0.067 ­ 0.941)
0.0019  
(0.18, 0.04 ­ 0.61)
<0.001  
(0.09, 0.02 ­ 0.3)
Yes 77.3 77.3 77.3
No 47.8 35.3 15.4
Radiotherapy 0.64  
(0.72, 0.13 ­ 2.61)
0.41  
(0.58, 0.1 ­ 2.14)
0.2  
(0.44, 0.08 ­ 1.63)
Yes 66.7 66.7 66.7
No 59.5 54.0 42.9
OS = overall survival; T = tumour extent (AIDS Clinical Trials Group staging); ART = antiretroviral therapy; IRR = incidence rate ratio; CI = confidence interval.
*Treatment groups are defined in the text and in Table 3.
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when considering the populations most burdened by HIV infection 
in SA, it highlights the burden of this advanced cancer in young 
people. The predominantly black racial distribution (85.7%) is not in 
keeping with the demographics of the Western Cape, where 48.8% of 
the population is coloured and 32.8% is black.[13] This points to the 
disproportionately high burden of AIDS­KS in black communities.
The median CD4+ count of 147 cells/µL was low despite two­
thirds of the patients being on ART at time of diagnosis for a median 
of just over 3 months. All but one of the remaining patients who 
were not on ART at diagnosis commenced ART soon thereafter. 
This attests to effective local ART initiation policies and stands in 
contrast to an AIDS­KS cohort from the same geographical area in 
the pre­ and early­ART era where only 47.3% of patients were on 
ART and the median CD4+ count was reported as 82 cells/µL.[5] It is 
notable that although just over half of the patients had undetectable 
VLs at time of assessment by the MKSC, more than two­thirds still 
had suboptimal KS responses on ART alone. The wide variation in 
recorded CD4+ and VL values as well as strict policies on the timing 
of these tests make it very difficult to relate specific values and even 
trends to AIDS­KS prognosis in daily practice and may support a 
more complex immunological interaction, as suggested by Maurer 
(Unemori et al.[14]).
Fourteen patients (33.3%) were on TB treatment and 4 had 
other OIs. It is important to note that some of these patients 
were empirically started on TB treatment despite negative sputum 
polymerase chain reaction (PCR) results, which could explain the 
higher rate of possible TB co­infection compared with the 19.1% 
reported in a pre­ART cohort from KwaZulu­Natal Province[11] but 
also calls into question the diagnosis of pulmonary TB (PTB) in 
patients who could have undiagnosed pulmonary KS. This scenario 
highlights the significant burden of disease and treatment toxicity 
carried by patients, who are often diagnosed with HIV, PTB and 
KS at the same time. The MDT approach proved crucial in making 
the difficult management decisions on the need for TB treatment 
in PCR­negative patients who may have pulmonary KS and require 
chemotherapy.
The large proportion of histological diagnoses (95.2%) differs 
dramatically from the 3% reported for the same area a decade 
earlier.[5] When the MKSC was started, all patients with AIDS­KS 
were seen regardless of T stage, but referral criteria have since been 
limited to T1 patients. Twenty patients (47.6%) were T1S1, which 
has been reported to be a poor prognostic subgroup.[15] High rates of 
lower limb and oral cavity involvement are in keeping with other SA 
cohorts.[5,6,11] The relatively low number of recorded pulmonary KS 
cases (11.9%) could be explained by the limited access to computed 
tomography scanning and the difficulty in distinguishing KS from 
PTB on plain chest films. Three of the 4 patients diagnosed with 
pulmonary KS were also on TB treatment. Pleuropulmonary KS 
is known to be a poor prognostic factor, and delayed diagnosis 
and treatment could have a negative impact on survival.[16] The 
diagnosis of GIT involvement is made on endoscopy with or without 
biopsy. The MKSC referred all patients with lower than normal 
haemoglobin levels or suspicious GIT complaints for endoscopy to 
rule out gastrointestinal involvement. Data on KS­associated immune 
reconstitution inflammatory syndrome (KS­IRIS) were not recorded.
Despite lack of evidence of a survival benefit beyond that achieved 
by ART, guidelines recommend the early initiation of chemotherapy 
for advanced, symptomatic or rapidly progressive AIDS­KS as an 
effective means to palliate symptoms.[17] The MKSC is regularly 
confronted with difficult treatment decisions that are complicated by 
late referrals, poor PS, serious co­infections and poor adherence to 
treatment. Twenty patients (47.6%) did not receive oncotherapy. This 
group can be divided into two very different prognostic subgroups, 
namely patients with T0/T1 disease responding clinically to ART, for 
which current guidelines suggest no additional therapy (group 1),[18] 
and patients with T1 disease not responding to ART, who had clinical 
indications for oncotherapy but were either unfit for or defaulted 
from oncotherapy (group 3).
Oncotherapy was initiated in 22 patients (52.4%) with T1 disease 
who were not responding optimally to ART alone (group 2). Primary 
treatment was chemotherapy in 14 cases (33.3%). Despite less than 
half the patients completing the intended course, the response at 
6 weeks for those who did attend scheduled follow­up was good. 
Primary therapy was RT in 8 cases (19.0%) and 5 patients went 
on to receive chemotherapy after RT, starting within 6 weeks of 
RT in 4 cases. In these cases, RT was intended to gain rapid local 
symptom control in advanced lesions and follow­on chemotherapy 
was planned to control extensive disease. Despite poor attendance at 
6 weeks after RT (44.4%), all patients had a PR. One patient received 
concurrent chemoradiation to 30.25 Gy.
The proportion of T1 patients receiving chemotherapy (52.8%) 
and RT (25.0%) differs from treatment patterns previously reported 
in the same geographical area and in Gauteng Province, in that 
patients were more likely to receive chemotherapy than RT.[5,6] 
This is in keeping with international guidelines and the current 
protocol of the MKSC in which chemotherapy with combination 
bleomycin and vincristine or paclitaxel as single agent is used in all 
patients considered fit for chemotherapy. Radiotherapy is reserved 
for chemoresistant or highly localised lesions, or patients with life­
threatening localised lesions when chemotherapy cannot be started 
urgently.[17] High rates of defaulting from oncology treatment (31.8%) 
and scheduled follow­up (77.3%) pose a significant challenge in the 
treatment of AIDS­KS in our cohort.
Our cumulative 2­year OS of 61.1% compares favourably with 
most other SA cohorts in the post­ART era and may suggest 
improvement in local outcomes.[5,12,19] Recently a 2­year OS rate 
of 79% was reported in an SA cohort treated in the late ART era, 
but this cohort included only 56.6% poor­risk patients compared 
with the 90.5% reported here and excluded patients with visceral 
disease.[6] A Nigerian AIDS­KS cohort with minimal access to 
chemotherapy reported a 1­year mortality rate of 22% and 1­year 
OS of 50 ­ 55%.[20] Overall, the outcomes are still markedly inferior 
to those of international cohorts.[15,21] When stratifying 2­year OS by 
 
 
Figure 3: T1 2yr OS by treatment group (p<0.001) 
 
 
Figure 4: 2yr OS by chemotherapy in T1 with suboptimal response to ART (p<0.001) 
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Fig. 4. Two-year overall survival according to chemotherapy in T1 with 
suboptimal response to ART (p<0.001). (Chemo = chemotherapy; T = 
tumour extent; ART = antiretroviral therapy.)
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the predefined treatment groups, a statistically significant difference 
is seen favouring groups 1 and 2 (p=0.0001) that persists when the T1 
subgroup is analysed. The 2­year OS for patients with a suboptimal 
response to ART and receiving oncotherapy (group 2) was 70.9%, 
which is remarkable considering that 40.0% were ACTG T1S1 and 
nearly a third had visceral disease or were on TB treatment. Patients 
with a suboptimal response to ART but not receiving oncotherapy 
(group 3) had a 2­year OS of 10% with only 30.0% surviving beyond 
3 months. This can probably be ascribed to delays in presentation and 
referral, but may also signify cases of KS­IRIS.
Despite retrospective cohorts suggesting that the addition of 
chemotherapy to ART may improve survival, this has not been 
prospectively validated.[5,6,19] In the T1 cohort, the addition of 
chemotherapy to ART improved 2­year OS markedly from 35.3% to 
77.3%. When T1 patients who were responding optimally to ART 
are excluded, 2­year OS without chemotherapy falls to 15.4%. This 
suggests that the timely addition of chemotherapy to ART could 
confer a survival advantage in T1 AIDS­KS. This finding should 
be interpreted with caution, as bias due to early deaths and lack 
of ART adherence data in group 3 could exist. There was a non­
significant trend towards a 2­year OS benefit for chemotherapy in 
the T1S1 subgroup (62.5% v. 28.6%), a group that is reported to have 
a particularly poor prognosis.[15] On a practical level, this addresses 
the often difficult decision the MKSC had to make when faced with 
very unwell patients. If these patients had any other solid tumour 
they would not be considered fit for chemotherapy, but in the setting 
of advanced HIV the poor PS could be ascribed to disseminated KS 
and they could obtain meaningful symptomatic improvement from 
even low doses of chemotherapy. No OS benefit was noted for the 
addition of RT to ART.
Other statistically significant associations on univariate analysis 
with inferior OS were S1 disease status (Fig. 1), any visceral 
involvement (Fig. 2), pulmonary involvement, PS >2, being on TB 
treatment and the presence of any OI. Most of these factors have 
been reported as known poor prognostic factors in AIDS­KS in the 
African setting.[5,6,16] ACTG T1 and I1 disease was not associated with 
poor prognosis.
The lack of association between a CD4+ count <150 cells/µL 
and survival along with the wide variation in CD4+ counts at 
diagnosis supports other reports that in African AIDS­KS the 
current ACTG cut­off of 150 cells/µL for S1 disease may not be an 
appropriate prognostic marker.[11,19] An alternative prognostic scale 
using incremental CD4+ counts, age, S1 disease and whether KS is 
the first AIDS­defining illness has been developed, but has not yet 
been validated in the African setting.[21] It is notable that in the S1 
subgroup, individual risk factors such as PS >2 and concurrent TB 
treatment were associated with poor survival. This association with 
poor survival was also true for visceral KS involvement, an entity 
that directly reflects disease burden but is not distinguished from 
other T1 presentations in the current ACTG staging system. These 
factors, particularly T1S1 disease stage and visceral KS, should be 
investigated to develop and validate prognostic indices for use in the 
sub­Saharan setting.
The issue of misdiagnosed pulmonary KS and PTB certainly 
warrants further study to determine the most cost­effective way of 
arriving at a diagnosis and thereby reducing delays in chemotherapy 
treatment, minimising unnecessary anti­TB treatment toxicity and 
improving prognostic accuracy.
Study limitations
The retrospective nature of the study lends itself to incomplete data 
collection and reporting bias as well as selection bias due to the 
site being a referral centre. Data on late relapse of KS, incidence of 
KS­IRIS and treatment toxicities were not known for all patients. 
Although verification of living status was reliably collected at time of 
censoring, the cause of death was not known in all patients. Owing to 
the small number of patients in the cohort, wide CIs were recorded 
during univariate analysis and it was found to be underpowered for 
multivariate analysis.
Conclusion
AIDS­KS affects young people in the Western Cape despite 10 years 
of ART roll­out. A significant proportion of patient are on concurrent 
TB treatment that could adversely affect diagnosis, adherence and 
response to treatment. A multidisciplinary approach to diagnosis, 
staging and treatment has been of benefit in this setting. Despite 
advanced disease at presentation and palliative treatment intent, 
survival outcomes are encouraging and seem to be positively affected 
by increased use of chemotherapy, despite suboptimal administration. 
Validation and exploration of prognostic indices specific to the sub­
Saharan setting, particularly T1S1 disease status and visceral KS, 
would be valuable in designing appropriate treatment algorithms. 
Efforts should be made to improve adherence to oncological therapy 
and follow­up, and adequate provision should be made for long­term 
palliative supportive services for this patient group.
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